AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03980444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group, no basket
Description: In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion.
Study NCT03921814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with IPL device
Description: Exposure of body parts to the IPL device
Study NCT03466086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Eye Drops
Description: blink® intensive TRIPLE ACTION 3 in 1 eye drops
Study NCT03466086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Eye Drops
Description: Systane® BALANCE eye drops
Study NCT01293058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal naloxone
Description: spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
Study NCT01293058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous
Description: Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
Study NCT01949870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: day1 and day8 at each cycle
Study NCT01949870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: day1 and day8 at each cycle
Study NCT01949870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Selumetinib
Description: 25mg/day, 50mg/day and 75mg/day
Study NCT03953235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C903
Description: a shared neoantigen cancer vaccine prime
Study NCT03953235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R904
Description: a shared neoantigen cancer vaccine boost
Study NCT03953235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody
Study NCT04420533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior therapy alone
Description: 1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~3. use of relaxed and double-voiding techniques;~4. urethral milking to prevent post-micturition dribble;~5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~6. bladder retraining that encourages men to hold on when they have sensory urgency;~7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;~9. treatment of constipation.
Study NCT03953235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: anti-CTLA-4 monoclonal antibody
Study NCT00994357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time CGM
Description: See previous description.
Study NCT00994357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: See text.
Study NCT04009369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct access to a PT
Description: Direct access to a PT in the ED immediately after triage and prior to physician assessment.
Study NCT02104622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk Rehabilitation 2.0
Study NCT04420533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior therapy alone
Description: 1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~3. use of relaxed and double-voiding techniques;~4. urethral milking to prevent post-micturition dribble;~5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~6. bladder retraining that encourages men to hold on when they have sensory urgency;~7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;~9. treatment of constipation.
Study NCT04420533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG Extended Release Oral Tablet
Description: Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
Study NCT02582060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thromboelastography/Thromboelastometry-Guided Treatment Regimen
Description: The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
Study NCT01894984 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
Study NCT02841280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
Study NCT02841280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a forced-titration study and placebo will be increased if goal BP is not achieved.
Study NCT01894984 — intervention group
Intervention type: DRUG
Intervention: Oral atypical anti-psychotic
Description: This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
Study NCT00911469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS902330
Description: 3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Study NCT00911469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
Study NCT02663063 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SSP treatment
Description: SSP treatment 5 times a week
Study NCT02663063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SSP treatment
Description: SSP treatment 5 times a week
Study NCT01630200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast coated tablet, 500µg oral application, once daily in the morning
Study NCT02156908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine 60 mg/kg
Study NCT01964144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
Study NCT01910480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854 50 mg capsule once daily
Study NCT01910480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg (200 mg twice daily)
Study NCT03674112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Description: PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
Study NCT03674112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab IV
Description: Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
Study NCT03674112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab IV
Description: Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Study NCT03857386 — intervention group
Intervention type: PROCEDURE
Intervention: PECS group
Description: Pecs block performed using ultrasound guidance
Study NCT03857386 — intervention group
Intervention type: PROCEDURE
Intervention: Control group
Description: Local infiltration anesthesia performed during the operation
Study NCT01630200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
Study NCT04296864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: monoclonal antibody
Study NCT04296864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: monoclonal antibody
Study NCT00275535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin
Description: Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
Study NCT00275535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
Study NCT00275535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
Study NCT00275535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
Study NCT00275535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
Study NCT00766207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: multi-faceted decision support
Study NCT00766207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stream-lined clinical alert
Description: electronic notification that a medication is potentially teratogenic
Study NCT02132364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: optimised follow-up
Description: optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
Study NCT01186445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine chlorhydrate
Description: 1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
Study NCT01186445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 3 ml of saline solution , intracoronary injection during reperfusion
Study NCT01982149 — intervention group
Intervention type: GENETIC
Intervention: Group 1
Description: Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
Study NCT01982149 — intervention group
Intervention type: GENETIC
Intervention: Group 2
Description: Correlate gene expression data from nasal and bronchial epithelium
Study NCT01982149 — intervention group
Intervention type: GENETIC
Intervention: Group 3
Description: Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
Study NCT04069000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based social-emotional learning program
Description: Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
Study NCT04069000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular grade 3 program
Description: Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
Study NCT01123382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulator
Description: A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
Study NCT01123382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Therapy
Description: Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
Study NCT03833297 — intervention group
Intervention type: DRUG
Intervention: Drugs inducing hepatological toxicity
Description: Drugs susceptible to induce hepatological toxicities
Study NCT03941275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bi-plane fluoroscopy
Description: In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
Study NCT04400864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: dietary counseling based on the principals pf the dietary intervention group.
Study NCT03512444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure System
Description: Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
Study NCT05973305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzol 20 mg/ml
Description: dosing schedule t.i.d.
Study NCT05973305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trusopt 20 mg/ml
Description: dosing schedule t.i.d.
Study NCT03243032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg given 30 minutes prior to beginning of surgery
Study NCT03243032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic Group 1
Description: 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
Study NCT03243032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
Study NCT03243032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local anesthetic Control
Description: 2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
Study NCT03943069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic bullectomy alone
Description: Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
Study NCT03943069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic bullectomy with pleurodesis
Description: Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
Study NCT04109391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TX05 (trastuzumab)
Description: Subjects will receive up to 13 cycles of adjuvant treatment.
Study NCT00319748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 852A
Description: 0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
Study NCT04415450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education counseling
Description: In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
Study NCT03495011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast MRI
Description: Quantitative, multiparametric breast MRI
Study NCT03495011 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fructose corn syrup
Description: High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aspartame
Description: Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy-balanced diet
Description: Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-balanced diet
Description: Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad libitum diet
Description: Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Study NCT02548767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum diet
Description: Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Study NCT06579729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention for low free sugars
Description: After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.